Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tarextumab + etoposide + cisplatin or carboplatin
- Development stage
- Discontinued
- Lead developer
- Mereo BioPharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is an investigational **combination regimen** for cancer, in which **tarextumab**, a fully human IgG2 monoclonal antibody targeting Notch2 and Notch3 receptors, is combined with the standard chemotherapeutic agents **etoposide** and a platinum agent (**cisplatin** or **carboplatin**)[2][3][7]. Tarextumab inhibits Notch2/Notch3-mediated signaling, impacting cancer stem cell survival, promoting tumor cell differentiation, and disrupting tumor angiogenesis[2][4][6][8]. Etoposide is a topoisomerase II inhibitor that interferes with DNA synthesis and repair, and both cisplatin and carboplatin are platinum-based agents causing DNA crosslinking and apoptosis in rapidly dividing cells. This combination, specifically studied in small cell lung cancer (SCLC), is given intravenously. The regimen was explored in clinical trials (notably the PINNACLE trial) for patients with untreated extensive-stage SCLC and evaluated for safety, tolerability, maximum tolerated dose, and preliminary efficacy[3][7].
- Other names
- tarextumab + etoposide + cisplatintarextumab + etoposide + carboplatin
02
Targets
NOTCH (Neurogenic locus notch homolog protein 3)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on tarextumab + etoposide + cisplatin or carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tarextumab + etoposide + cisplatin or carboplatin.